FRANKLIN, Mass., Jan 11 /PRNewswire-FirstCall/ -- Echo Therapeutics, Inc. , a company developing the needle-free Symphony(TM) tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude(TM) SkinPrep System for transdermal drug delivery, announced today that the Company has completed the product development work for its Prelude SkinPrep System and now has the commercially ready product to be used in final clinical trials.
“The completion of the product development work on our Prelude SkinPrep System, our skin preparation platform technology used for both transdermal drug delivery and skin preparation prior to the application of the Symphony tCGM glucose biosensor represents one of the most important milestone events in the Company’s history,” stated Patrick T. Mooney, M.D., Chairman and CEO of Echo Therapeutics. “We are now prepared to complete our clinical validation and begin commercialization efforts in enhanced topical lidocaine delivery. This next generation skin preparation device incorporates substantial improvements beyond the prototype used in earlier studies. We anticipate testing Prelude with LMX4 anesthetic cream for enhanced local dermal anesthesia in the near-term and subsequently seeking 510-k market clearance from the FDA.”
About Echo Therapeutics
Cautionary Statement Regarding Forward Looking Statements
(C) 2002 - 2009 Echo Therapeutics, Inc. All rights reserved worldwide.
CONTACT: Patrick T. Mooney, M.D., Chairman and Chief Executive Officer,
Echo Therapeutics, Inc., +1-508-530-0329; or Jeffrey Stanlis, Partner,
Hayden IR, +1-602-476-1821 for Echo Therapeutics, Inc.
Web site: http://www.echotx.com/
